July 10
IN THIS ISSUE / July 10, 2019
- FDA clears new body sculpting device
- DW Insights and Inquiries: The pachydermoperiostosis prostaglandin paradigm
- Increase in demand triggers shortage of intravenous immunoglobulin
- Patient Access Hero: Dallas clinic provides free multidisciplinary care
- Miami Beach Commission Sustainability and Resiliency Committee rejects sunscreen ingredient ban
FDA clears new body sculpting device
Allergan has announced that the U.S. Food and Drug Administration has cleared its CoolTone device for toning, firming, and strengthening the buttocks, thighs, and abdomen. According to Allergan, the device creates muscle contractions by utilizing magnetic muscle simulation technology. The contractions stimulate muscle fibers, which may result in muscle strength and conditioning.
From fat freezing, to ultrasound, to bile acid injections, what are the options for patients seeking non-invasive fat-reduction? Read more in Dermatology World.
Related Content:
- Expanding your cosmetic services – Dermatology World (May 2019)
- Cosmetic concerns and considerations – Dermatology World (January 2018)
DW Insights and Inquiries: The pachydermoperiostosis prostaglandin paradigm
Prostaglandins were the rage when I started medical school in 1975; their role in inflammatory dermatoses was considered of paramount importance throughout my residency in the early 1980s. Hours were spent studying the transformation of arachidoinic acid to prostaglandins and leukotrienes, via the respective cyclo-oxygenase and lipoxygenase pathways. In his 1982 Ingram Lecture, Malcom Greaves stated: “The story of prostaglandins (PGs) is in itself a remarkable one, beginning in 1935 with semen and arriving in 1982 in the skin, with a long way to go yet.”
This commentary was inspired by a case report with an impressive result, based on understanding molecular mechanisms, leading to treatment modifying of an “old” pathway — the rapid improvement of pachydermoperiostosis (PDP) with etoricoxib (a COX-2 inhibitor). Keep reading!
Increase in demand triggers shortage of intravenous immunoglobulin
Physicians and patients are reporting a current shortage of IVIG (intravenous immunoglobulin) in the United States due to a nationwide increase in demand that has exceeded manufacturing supply. According to the Immune Deficiency Foundation, there is a global shortage of the plasma supply.
The AADA is aware of the shortage and is monitoring the situation. Stay tuned to DWW for updates.
Related Content:
Patient Access Hero: Dallas clinic provides free multidisciplinary care
Every Saturday morning a group of dermatologists from UT Southwestern Medical Center volunteers at the Agape Clinic, a free clinic in Dallas that provides cross-specialty health care to people who otherwise have no access to care. Learn more about why David Harker, MD, one of the volunteers, says the service is not just a profession, but a calling.
The Academy seeks stories that highlight dermatologists’ role as partners in the health care system, providing expert care for serious conditions. Share your story.
Related Content:
Miami Beach Commission Sustainability and Resiliency Committee rejects sunscreen ingredient ban
The Miami Beach Commission’s Sustainability and Resiliency Committee rejected a recent proposal that would prohibit the sale of sunscreens containing the ingredients oxybenzone or octinoxate. The AADA recently sent a letter to the Mayor of Miami Beach, Dan Gelber, and all the members of the Commission, addressing its concerns regarding the proposal.
Do your patients have questions about sun protection and sunscreen safety? Download the Academy’s infographic that offers information on how patients can protect against skin cancer, as well as the difference between physical sunscreen and chemical sunscreen.
Related Content:
